drugset / Trial / NCT05559008
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, prospective, open-label, interventional umbrella study to evaluate the efficacy and safety of targeted therapies guided by molecular subtypes in patients with relasped or refractory peripheral T-cell lymphoma.
Timeline
- Start
- 2022-09-30
- Primary completion
- 2024-03-26
- Completion
- 2026-01-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Linperlisib | Small molecule | — | Oral |
| Subject | Rivoceranib | Small molecule | — | — |
| Subject | SHR2554 | Small molecule | — | Oral |
| Subject | Tucidinostat | Small molecule | — | Oral |
| Subject | dasatinib anhydrous | Small molecule | — | Oral |